The 2015 ISDB General Assembly, Pamplona, Spain, from June 27th to 30th, 2015.
On July 1st there will be a workshop on GRADE method to grading quality of evidence and strength of recommendations. You are also kindly invited to participate in it.
Read more…
European Directive on trade secrets: the JURI Committee must profoundly improve this text
Joint open Letter to the members of the JURI Committee from the Corporate Europe Observatory (CEO), The Medicines in Europe Forum (MiEF) and The International Society of Drug Bulletins (ISDB) calling on the members of the JURI Committee to ensure, through additional and more ambitious amendments, that both freedom of speech for journalists and their sources, including whistle-blowers, and access to regulatory and scientific data of public interest, are preserved.
EU Clinical Trials Regulation: EMA steers away from transparency by misinterpreting exception provisions
Joint response to an EMA public consultation
The European Medicines Agency (EMA) must stay true to the Clinical Trials Regulation: non-disclosure has to remain the exception, not become the norm!
Press release and joint response attached as PDF:
European Directive on trade secrets: A threat to access to public health data
Joint briefing paper
The proposed EU directive on the protection of trade secrets currently being studied by the European Parliament threatens freedom of speech for journalists and whistle-blowers, and access to scientific data of public interest.
EU trade secrets directive a threat to health, environment, free speech and worker mobility
Joint statement
The proposed trade secrets directive could obstruct recent EU developments on transparency and endangers freedom of information and expression of European citizens. A multi-sectoral NGO coalition calls for greater protections for consumers, journalists, whistleblowers, researchers and workers. Joint statement attached.